BioAge Labs
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechUses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102. | Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102. | bioagelabs.com |
Events
| Date | Event | ||
|---|---|---|---|
| Dec 4, 2025 | BioAge reports interim Phase 1 data for NLRP3 inhibitor BGE-102sec.gov· Milestone· Longevity biotech | Longevity biotech | Milestone |
| Sep 26, 2024 | BioAge Labs prices its Nasdaq IPOsec.gov· Deal· Longevity biotech | Longevity biotech | Deal |
Funding
About
- Source
- bioagelabs.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | BioAge LabsCompany in Longevity biotech: Joined a field, Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102. | seed | bioagelabs.com |
| Sep 25, 2026 | BioAge LabsCompany: Added | seed | bioagelabs.com |